Benzinga | Feb 24, 2021 05:17AM EST

Needham Maintains Strong Buy on Esperion Therapeutics, Lowers Price Target to $134

Needham analyst Chad Messer maintains Esperion Therapeutics (NASDAQ:ESPR) with a Strong Buy and lowers the price target from $150 to $134.